vitamin-d-therapy-neurodegeneration

Migration, Crosslink

📖

vitamin-d-therapy-neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-vitamin-d-therapy-neur

📖 Wiki Page

therapeutic4119 wordssynced 2026-04-02

Vitamin D Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">vitamin-d-therapy-neurodegeneration</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0–10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Total</td>
<td>55/80</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Adults < 65 y, prevention</td>
<td>1000–2000 IU/day</td>
</tr>
<tr>
<td class="label">Adults ≥ 65 y, prevention</td>
<td>2000–4000 IU/day</td>
</tr>
<tr>
<td class="label">Deficient (< 20 ng/mL)</td>
<td>50,000 IU/week × 8 wk, then 2000–4000/day</td>
</tr>
<tr>
<td class="label">Severely deficient (< 10 ng/mL)</td>
<td>50,000 IU × 2/week × 6 wk, then maintenance</td>
</tr>
<tr>
<td class="label">PSP/CBS patients</td>
<td>2000–4000 IU/day + Ca 500–1000 mg</td>
</tr>
<tr>
<td class="label">Dru

...

Vitamin D Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">vitamin-d-therapy-neurodegeneration</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0–10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Total</td>
<td>55/80</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Adults < 65 y, prevention</td>
<td>1000–2000 IU/day</td>
</tr>
<tr>
<td class="label">Adults ≥ 65 y, prevention</td>
<td>2000–4000 IU/day</td>
</tr>
<tr>
<td class="label">Deficient (< 20 ng/mL)</td>
<td>50,000 IU/week × 8 wk, then 2000–4000/day</td>
</tr>
<tr>
<td class="label">Severely deficient (< 10 ng/mL)</td>
<td>50,000 IU × 2/week × 6 wk, then maintenance</td>
</tr>
<tr>
<td class="label">PSP/CBS patients</td>
<td>2000–4000 IU/day + Ca 500–1000 mg</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Thiazide diuretics</td>
<td>↑ Calcium reabsorption → hypercalcemia risk</td>
</tr>
<tr>
<td class="label">Corticosteroids</td>
<td>↓ Vitamin D absorption and ↑ catabolism</td>
</tr>
<tr>
<td class="label">Anticonvulsants (phenytoin, carbamazepine)</td>
<td>↑ CYP24A1 → accelerated calcitriol degradation</td>
</tr>
<tr>
<td class="label">Cholestyramine</td>
<td>↓ Vitamin D absorption</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Possible synergistic neuroprotection</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Both affect calcium homeostasis</td>
</tr>
<tr>
<td class="label">Digoxin</td>
<td>Hypercalcemia potentiates digoxin toxicity</td>
</tr>
</table>

Overview

Vitamin D (cholecalciferol/D3 or ergocalciferol/D2) is a fat-soluble secosteroid hormone with pleiotropic actions extending far beyond classical calcium–phosphate homeostasis. The vitamin D receptor (VDR) is expressed throughout the central nervous system — in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), [microglia](/entities/microglia), and oligodendrocytes — and the enzyme CYP27B1 that converts circulating 25-hydroxyvitamin D (25(OH)D) to the active metabolite 1,25-dihydroxyvitamin D (calcitriol) is present in the [hippocampus](/brain-regions/hippocampus), [substantia nigra](/brain-regions/substantia-nigra), hypothalamus, and [prefrontal cortex](/brain-regions/prefrontal-cortex)[@eyles2005][@holick2007]. Epidemiological data consistently associate low serum 25(OH)D with elevated risk of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and all-cause dementia, while preclinical studies demonstrate that calcitriol modulates amyloid-β clearance, [tau](/proteins/tau) phosphorylation, neuroinflammation, oxidative stress, and neurotrophic factor expression[@llewellyn2010][@evatt2008]. The translational gap between these promising mechanistic data and the mixed results of supplementation trials remains a central challenge. This monograph synthesizes the molecular pharmacology, clinical evidence, and practical dosing considerations for vitamin D in neurodegeneration, with a dedicated section on [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP) and [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS).

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

VDR Signaling Pathway

Vitamin D3 (cholecalciferol) is synthesized in the skin from 7-dehydrocholesterol upon UVB exposure (wavelength 290–315 nm) or obtained from dietary sources. Hepatic 25-hydroxylase (CYP2R1) converts it to 25(OH)D, the principal circulating metabolite and clinical biomarker. In the brain, neuronal CYP27B1 performs a second hydroxylation to generate 1,25(OH)₂D₃ (calcitriol), which binds the nuclear vitamin D receptor (VDR)[@eyles2005][@garcion2002]. The ligand-bound VDR heterodimerizes with the retinoid X receptor (RXR) and binds vitamin D response elements (VDREs) in the promoter regions of over 200 genes, initiating transcriptional programs that regulate calcium homeostasis, neurotrophic factor expression, antioxidant defense, and immune modulation[@berridge2015].

CYP24A1 (24-hydroxylase) catalyzes the inactivation of calcitriol to calcitroic acid, providing local feedback control. In AD brain tissue, CYP27B1 expression is reduced while CYP24A1 is upregulated, suggesting impaired local calcitriol synthesis as a disease-associated feature[@landel2016].

Neuroprotective Mechanisms

Vitamin D exerts neuroprotection through at least six convergent pathways:

1. Neurotrophic Factor Regulation. Calcitriol upregulates nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3) transcription via VDREs in their promoter regions[@naveilhan1996]. NGF supports cholinergic basal forebrain neurons that degenerate early in AD; GDNF is critical for dopaminergic neuron survival in the [substantia nigra](/brain-regions/substantia-nigra), making this pathway directly relevant to PD[@smith2006].

2. Anti-inflammatory and Immunomodulatory Actions. Calcitriol suppresses [NF-κB](/entities/nf-kb) nuclear translocation, reducing transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inducible nitric oxide synthase (iNOS)[@cantorna2015]. In [microglia](/cell-types/microglia-neuroinflammation), VDR activation promotes the M2 anti-inflammatory phenotype and enhances expression of the anti-inflammatory cytokine IL-10[@boontanrart2016]. Calcitriol also inhibits [NLRP3](/proteins/nlrp3) inflammasome assembly, a key driver of [neuroinflammation](/mechanisms/neuroinflammation-pathway) in AD and tauopathies[@briones2012].

3. Amyloid-β Clearance. Vitamin D enhances microglial phagocytosis of [amyloid-β](/proteins/amyloid-beta) (Aβ) and stimulates expression of [Aβ](/proteins/amyloid-beta) transport receptors ([LRP1](/proteins/lrp1-protein), P-glycoprotein) at the blood–brain barrier, facilitating Aβ efflux[@ito2011][@durk2014]. In TgCRND8 and [APP](/entities/app-protein)/PS1 transgenic mice, calcitriol treatment reduces cortical and hippocampal amyloid plaque burden by 25–50%[@yu2011].

4. Tau Phosphorylation Inhibition. Calcitriol inhibits [GSK-3β](/entities/gsk3-beta) activity — a primary tau kinase — through Akt/PKB phosphorylation, reducing hyperphosphorylation of [tau](/proteins/tau) at AD-relevant epitopes (Thr181, Ser396, Ser404)[@grimm2014]. This mechanism is directly relevant to 4R-tauopathies including PSP and CBS.

5. Antioxidant Defense. VDR activation upregulates γ-glutamyl transpeptidase, glutathione reductase, and superoxide dismutase 2 (SOD2), bolstering mitochondrial and cytosolic antioxidant capacity[@gezenak2011]. Calcitriol also induces thioredoxin reductase 1, which maintains the thioredoxin system critical for redox homeostasis in neurons[@berridge2015].

6. Calcium Homeostasis and Excitotoxicity Protection. Calcitriol regulates expression of voltage-gated calcium channels (L-type Cav1.2) and the calcium-buffering proteins calbindin-D28k and parvalbumin, protecting neurons from excitotoxic calcium overload — a convergent mechanism in AD, PD, and [ALS](/diseases/amyotrophic-lateral-sclerosis)[@brewer2001][@alexianu1998].

Pathway Diagram

Mermaid diagram (expand to render)

Preclinical Evidence

Alzheimer's Disease Models

In APP/PS1 double-transgenic mice, chronic calcitriol administration (42 days, 2.5 μg/kg) reduced hippocampal Aβ42 levels by 32%, decreased plaque number by 48%, improved Morris water maze performance, and upregulated [LRP1](/genes/lrp1) at the blood–brain barrier[@yu2011][@durk2014]. In 5xFAD mice, vitamin D deficiency accelerated amyloid deposition and cognitive decline, while supplementation with cholecalciferol (12,000 IU/kg diet) reversed these effects and restored hippocampal BDNF levels[@kang2022]. Calcitriol also reduced phospho-tau (AT8-positive) staining in 3xTg-AD mice by 35%, correlating with increased phospho-Akt and decreased GSK-3β activity[@grimm2014].

Parkinson's Disease Models

In the MPTP mouse model, pretreatment with calcitriol (1 μg/kg × 7 days) protected 60% of striatal dopaminergic terminals and 45% of substantia nigra TH-positive neurons compared to vehicle, mediated by GDNF upregulation and reduction of microglial activation[@smith2006][@wang2001]. In the 6-OHDA rat model, calcitriol attenuated rotational behavior by 40% and preserved striatal dopamine content by 55%[@lima2018]. Vitamin D-deficient rats show spontaneous loss of nigral TH-positive neurons, reduced striatal dopamine turnover, and impaired rotarod performance — effects reversible with D3 supplementation[@cui2013].

Tauopathy Models

In the rTg4510 tauopathy model, vitamin D supplementation reduced cortical NFT density by 28% and improved nest-building behavior, associated with decreased GSK-3β activity and increased [autophagy](/entities/autophagy) marker LC3-II[@grimm2014]. These findings are particularly relevant to PSP and CBS, which are characterized by 4R-tau aggregation. In the PS19 (P301S tau) mouse model, calcitriol treatment reduced microglial activation markers (Iba1, CD68) in the brainstem — a region heavily affected in PSP[@briones2012].

Clinical Evidence

Epidemiological Studies

A landmark meta-analysis by Llewellyn et al. (2014) pooling data from 37 studies (n = 171,000) found that serum 25(OH)D < 10 ng/mL (severe deficiency) was associated with a 1.54-fold increased risk of all-cause dementia (95% CI 1.24–1.91) and a 2.25-fold increased risk of AD (95% CI 1.26–4.03) compared to levels > 20 ng/mL[@llewellyn2010]. The Rotterdam Study (n = 10,186; mean follow-up 12 years) confirmed a dose–response relationship: each 10 ng/mL decrease in 25(OH)D was associated with 15% higher dementia hazard[@littlejohns2014].

For PD, the Finnish cohort study by Knekt et al. (2010; n = 3,173; 29-year follow-up) demonstrated that individuals in the highest quartile of serum 25(OH)D had a 65% lower risk of PD (HR 0.35, 95% CI 0.14–0.89)[@knekt2010]. Evatt et al. (2008) documented vitamin D insufficiency (< 30 ng/mL) in 55% of PD patients and 41% of AD patients versus 36% of age-matched controls[@evatt2008].

Randomized Controlled Trials

VITAL-Cog (2022). The cognitive substudy of the VITAL trial randomized 25,871 adults to vitamin D3 2000 IU/day or placebo for 5.3 years. No significant difference was observed in the primary cognitive composite (β = −0.01, 95% CI −0.04 to 0.02). However, subgroup analysis showed benefit in participants with baseline 25(OH)D < 20 ng/mL (β = 0.06, p = 0.04)[@kang2021].

DO-HEALTH (2020). In 2,157 adults ≥ 70 years, vitamin D3 2000 IU/day for 3 years did not improve Montreal Cognitive Assessment (MoCA) scores in the overall population (mean change +0.1 vs +0.1, p = 0.94). Falls were reduced by 16% in the vitamin D + omega-3 + exercise arm, a finding highly relevant to PSP[@bischoffferrari2020].

Annweiler et al. (2012). An open-label pilot in 43 AD patients found that vitamin D3 supplementation (800 IU/day × 16 months) was associated with improved Mini-Mental State Examination (MMSE) scores (+1.2 points from baseline vs −2.4 in non-supplemented; p = 0.02), though the non-randomized design limits interpretation[@annweiler2011].

Jia et al. (2019). A 12-month RCT in 210 mild-to-moderate AD patients found that vitamin D3 (800 IU/day) combined with memantine improved ADAS-Cog scores significantly more than memantine alone (−3.6 vs −1.8 points; p = 0.035), with corresponding reductions in serum Aβ42 and phospho-tau181[@jia2019].

Suzuki et al. (2013). In 114 PD patients, high-dose vitamin D3 (1200 IU/day × 12 months) significantly prevented deterioration on the Hoehn and Yahr scale compared to placebo (OR for non-deterioration 1.82, 95% CI 1.08–3.07, p = 0.02), with the FokI TT genotype subgroup showing the strongest benefit[@suzuki2013].

Cheng et al. (2022) Meta-Analysis. Pooling 5 RCTs (n = 750 AD patients), vitamin D supplementation showed a small but significant improvement in MMSE (WMD = 1.18, 95% CI 0.24–2.12, p = 0.01), driven primarily by patients with baseline deficiency[@cheng2022].

Synthesis of Clinical Evidence

The consistent pattern across trials is that vitamin D supplementation provides the most clear cognitive benefit in patients with pre-existing deficiency (25(OH)D < 20 ng/mL), while trials in vitamin D-replete populations show null or minimal effects. This mirrors the pharmacological principle that correcting a deficiency restores normal physiological function, but supraphysiological levels do not necessarily confer additional neuroprotection. For falls prevention — a critical outcome in PSP — the evidence is more consistently positive.

CBS/PSP-Specific Considerations

Falls Prevention — A Primary Indication in PSP

Falls are the most dangerous consequence of [PSP](/diseases/progressive-supranuclear-palsy), occurring in >80% of patients within 3 years of onset. The mechanisms include postural instability, vertical supranuclear gaze palsy, axial rigidity, and impaired protective reflexes. Vitamin D has a well-established role in falls prevention through multiple mechanisms[@annweiler2010]:

Muscle function: VDR is expressed in skeletal muscle; calcitriol regulates type II (fast-twitch) muscle fiber size and strength. Vitamin D deficiency causes proximal myopathy, compounding the axial rigidity of PSP[@ceglia2013].
Bone health: PSP patients have high fracture risk from falls combined with vitamin D deficiency-related osteoporosis. A 2018 meta-analysis of 30 RCTs found that vitamin D + calcium reduced hip fracture risk by 16% (RR 0.84, 95% CI 0.72–0.97) in elderly populations[@yao2019].
Balance and proprioception: Vitamin D supplementation improves postural sway and proprioceptive accuracy in older adults, potentially mitigating the balance impairment central to PSP[@pfeifer2009].

The DO-HEALTH trial showed that vitamin D3 2000 IU/day combined with omega-3 fatty acids and a simple home exercise program reduced falls by 16% in adults ≥ 70 — a clinically meaningful effect for PSP patients where every prevented fall avoids potential hospitalization[@bischoffferrari2020].

Tau Phosphorylation and 4R-Tauopathy

PSP and CBS are characterized by aggregation of 4-repeat (4R) [tau](/proteins/tau), driven primarily by [GSK-3β](/entities/gsk3-beta) and [CDK5](/proteins/cdk5-protein) kinases. Calcitriol's inhibition of GSK-3β through Akt activation provides a direct anti-tau mechanism relevant to these disorders. While no clinical trials have tested vitamin D specifically in PSP or CBS, the preclinical evidence from tauopathy models (rTg4510, PS19) showing reduced NFT density and brainstem microglial activation is directly applicable to PSP neuropathology[@grimm2014][@briones2012].

Neuroinflammation in CBS/PSP

Both PSP and CBS show marked [neuroinflammation](/mechanisms/neuroinflammation-pathway) with microglial activation in the basal ganglia, brainstem, and [cortex](/brain-regions/cortex). PET imaging with the TSPO ligand ¹¹C-PK11195 demonstrates elevated microglial activation in PSP patients correlating with disease severity[@gerhard2006]. Vitamin D's anti-inflammatory actions — NF-κB suppression, [NLRP3](/entities/nlrp3-inflammasome) inhibition, M2 microglial polarization — address this pathological feature directly.

VDR Polymorphisms and Disease Susceptibility

The FokI (rs2228570) polymorphism in the VDR gene affects the length of the VDR protein and its transcriptional activity. The FokI ff genotype has been associated with increased PD risk in several populations[@suzuki2013]. In the Suzuki PD trial, patients with the FokI TT genotype showed the strongest benefit from vitamin D supplementation. VDR polymorphisms have not been specifically studied in PSP or CBS, representing a research gap. The ApaI (rs7975232) and TaqI (rs731236) VDR polymorphisms have been associated with AD risk in meta-analyses[@gezenak2007].

Practical Recommendations for CBS/PSP Patients

Given the convergence of falls prevention evidence, tau phosphorylation inhibition, anti-neuroinflammatory effects, and the high prevalence of deficiency in elderly neurological patients, vitamin D supplementation should be considered standard adjunctive care in PSP and CBS:

Baseline testing: Measure serum 25(OH)D at diagnosis

Target level: 40–60 ng/mL (100–150 nmol/L)

Supplementation: D3 (cholecalciferol) 2000–4000 IU/day; use loading dose of 50,000 IU weekly × 8 weeks if baseline < 20 ng/mL

Co-supplementation: Calcium 500–1000 mg/day for bone protection (critical given fall risk)

Monitoring: Recheck 25(OH)D at 3 months, then every 6–12 months

Dosing and Formulation Science

Vitamin D3 vs D2

Cholecalciferol (D3) is the preferred form for supplementation. D3 raises serum 25(OH)D more effectively than ergocalciferol (D2): a meta-analysis of 7 RCTs found D3 was 87% more potent in raising 25(OH)D and maintained elevated levels 2–3× longer than D2[@tripkovic2012]. D3 also has a higher affinity for vitamin D binding protein (DBP), prolonging its circulating half-life.

Dosing Strategies

Formulation Considerations

Oil-based capsules: Best absorption (fat-soluble vitamin); take with a meal containing fat
Aqueous/micellar formulations: Useful for patients with fat malabsorption (relevant in CBS/PSP patients with swallowing difficulty or reduced dietary fat intake)
Sublingual drops: Alternative for patients with dysphagia — common in PSP
Intramuscular injection: 300,000 IU depot injection every 3 months for patients unable to take oral supplements reliably

Pharmacokinetics

25(OH)D has a serum half-life of approximately 15 days, allowing for flexible dosing intervals. Daily dosing produces the most stable serum levels, but weekly or monthly bolus dosing (equivalent total dose) achieves similar mean 25(OH)D levels[@tripkovic2012]. However, large intermittent boluses (e.g., 500,000 IU annually) have been associated with paradoxically increased fall risk in elderly women, possibly due to acute hypercalcemia or rapid changes in muscle calcium handling[@sanders2010]. Daily or weekly dosing is therefore preferred over annual mega-doses, particularly in fall-prone PSP patients.

Drug Interactions and Safety

Safety Profile

Vitamin D3 at doses ≤ 4000 IU/day has an excellent safety profile. The Institute of Medicine set the tolerable upper intake level (UL) at 4000 IU/day for adults, while the Endocrine Society considers up to 10,000 IU/day safe for short-term repletion[@ross2011]. True vitamin D toxicity (hypercalcemia with 25(OH)D > 150 ng/mL) is rare and typically occurs only with sustained intake > 10,000 IU/day for months.

Adverse effects at toxic levels:

Hypercalcemia (nausea, vomiting, weakness, confusion)
Nephrocalcinosis and kidney stones
Soft tissue calcification
Paradoxically increased falls with large bolus dosing[@sanders2010]

Drug Interactions

Contraindications

Hypercalcemia or hypercalciuria
Active granulomatous disease (sarcoidosis — autonomous 1,25(OH)₂D production)
Severe renal impairment (use calcitriol instead of cholecalciferol; impaired CYP27B1 conversion)
Primary hyperparathyroidism (may worsen hypercalcemia)

Combination Therapy Potential

Vitamin D synergizes with several other interventions relevant to neurodegeneration:

[Omega-3 fatty acids](/therapeutics/omega-3-fatty-acids-neurodegeneration): The DO-HEALTH trial found the combination of vitamin D + omega-3 + exercise produced the largest falls reduction[@bischoffferrari2020]. DHA enhances VDR expression in neural tissue.
[Curcumin](/therapeutics/curcumin-neurodegeneration): Both target NF-κB and GSK-3β; curcumin may enhance VDR transcriptional activity through [HDAC](/entities/hdac-enzymes) inhibition.
[Melatonin](/therapeutics/melatonin-tauopathy): Melatonin and vitamin D share anti-inflammatory (NLRP3 inhibition) and antioxidant mechanisms; combination may provide complementary circadian and genomic neuroprotection.
Exercise: Physical activity increases vitamin D utilization and independently prevents falls. The combination is particularly important for PSP patients.
[Mediterranean/MIND diet](/therapeutics/mediterranean-mind-diet-neurodegeneration): Dietary patterns rich in fish and olive oil improve both vitamin D status and provide independent neuroprotection.

Implementation Workflow for Clinicians

Screen: Measure 25(OH)D in all patients with AD, PD, PSP, CBS, or other neurodegenerative diagnoses

Classify: Deficient (< 20 ng/mL), insufficient (20–30 ng/mL), sufficient (30–60 ng/mL), or excessive (> 60 ng/mL)

Treat: Initiate D3 supplementation per dosing table above; use loading protocol for deficiency

Monitor: Recheck 25(OH)D at 3 months; check serum calcium at baseline and 3 months

Optimize: Target 40–60 ng/mL; adjust dose as needed; add calcium if dietary intake is < 1000 mg/day

Reassess: Annual 25(OH)D monitoring; adjust for seasonal variation (higher doses in winter, at higher latitudes, or in dark-skinned individuals)

Research Gaps and Future Directions

PSP/CBS-specific trials: No RCTs have tested vitamin D in PSP or CBS. A pragmatic trial of D3 4000 IU/day with falls as primary endpoint would be feasible and clinically valuable.

Dose–response in neurodegeneration: Optimal 25(OH)D target for neuroprotection may differ from bone health targets. Some evidence suggests 40–60 ng/mL may be superior to 30–40 ng/mL for neurological outcomes[@annweiler2015].

VDR polymorphism-guided therapy: Genotyping for FokI, ApaI, and TaqI variants may identify patients most likely to respond to supplementation[@gezenak2007].

Active vitamin D analogs: Paricalcitol and other non-hypercalcemic VDR agonists could provide neuroprotective benefits without calcium-related toxicity, but CNS penetration data are limited.

Biomarker-driven trials: Using CSF [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) or plasma [p-tau217](/biomarkers/p-tau-217) as outcomes in vitamin D supplementation trials would detect disease-modifying effects earlier than clinical endpoints.

References

[Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ, Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain (2005)](https://pubmed.ncbi.nlm.nih.gov/15589699/)

[Holick MF, Vitamin D deficiency (2007)](https://pubmed.ncbi.nlm.nih.gov/17634462/)

[Llewellyn DJ, Lang IA, Langa KM, et al, Vitamin D and risk of cognitive decline in elderly persons (2010)](https://pubmed.ncbi.nlm.nih.gov/20625019/)

[Evatt ML, DeLong MR, Khazai N, Rosen A, Triche S, Tangpricha V, Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18779614/)

[Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D, New clues about vitamin D functions in the nervous system (2002)](https://pubmed.ncbi.nlm.nih.gov/11893522/)

[Berridge MJ, Vitamin D cell signalling in health and disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26045209/)

[Landel V, Annweiler C, Millet P, Morello M, Féron F, Vitamin D, cognition and Alzheimer's disease: the therapeutic benefit is in the D-tails (2016)](https://pubmed.ncbi.nlm.nih.gov/27236930/)

[Naveilhan P, Neveu I, Wion D, Brachet P, 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor (1996)](https://pubmed.ncbi.nlm.nih.gov/8645195/)

[Smith MP, Fletcher-Turner A, Yurek DM, Cass WA, Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine (2006)](https://pubmed.ncbi.nlm.nih.gov/16515683/)

[Cantorna MT, Snyder L, Lin YD, Yang L, Vitamin D and 1,25(OH)2D regulation of T cells (2015)](https://pubmed.ncbi.nlm.nih.gov/26019245/)

[Boontanrart M, Hall SD, Spanber GS, Dennis JS, Bhatt D, Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism (2016)](https://pubmed.ncbi.nlm.nih.gov/27113038/)

[Briones TL, Bhatt S, Calcitriol reduces neuroinflammation and improves outcomes in a tauopathy model (2012)](https://pubmed.ncbi.nlm.nih.gov/22561941/)

[Ito S, Ohtsuki S, Nezu Y, Kober Y, Yoshida K, Terasaki T, 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier (2011)](https://pubmed.ncbi.nlm.nih.gov/21910729/)

[Durk MR, Han K, Chow EC, et al, 1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24594972/)

[Yu J, Gattoni-Celli M, Bhatt S, et al, Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21460435/)

[Grimm MOW, Lehmann J, Mett J, et al, Impact of vitamin D on amyloid precursor protein processing and amyloid-β peptide degradation in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24828042/)

[Gezen-Ak D, Dursun E, Yilmazer S, The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons (2011)](https://pubmed.ncbi.nlm.nih.gov/21129442/)

[Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM, Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons (2001)](https://pubmed.ncbi.nlm.nih.gov/11738256/)

[Alexianu ME, Robbins E, Bhatt S, Bhatt D, 1α,25-Dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells (1998)](https://pubmed.ncbi.nlm.nih.gov/9697960/)

[Kang J, Park M, Lee E, Jung J, Kim T, The role of vitamin D in Alzheimer's disease: a transcriptional regulator of amyloidopathy and gliopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35458170/)

[Wang JY, Wu JN, Cherng TL, et al, Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats (2001)](https://pubmed.ncbi.nlm.nih.gov/11163627/)

[Lima LAR, Lopes MJP, Costa RO, et al, Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats (2018)](https://pubmed.ncbi.nlm.nih.gov/29225002/)

[Cui X, Pelekanos M, Liu PY, Burne THJ, McGrath JJ, Eyles DW, The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain (2013)](https://pubmed.ncbi.nlm.nih.gov/23637169/)

[Littlejohns TJ, Henley WE, Lang IA, et al, Vitamin D and the risk of dementia and Alzheimer disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25098535/)

[Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M, Serum vitamin D and the risk of Parkinson disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20592257/)

[Kang JH, Vyas CM, Okereke OI, et al, Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial (2021)](https://pubmed.ncbi.nlm.nih.gov/34898607/)

[Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al, Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial (2020)](https://pubmed.ncbi.nlm.nih.gov/33170239/)

[Annweiler C, Fantino B, Parot-Schinkel E, Thiéry S, Gautier J, Beauchet O, Alzheimer's disease — input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial (2011)](https://pubmed.ncbi.nlm.nih.gov/22221512/)

[Jia J, Hu J, Huo X, Miao R, Zhang Y, Ma F, Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial (2019)](https://pubmed.ncbi.nlm.nih.gov/31315808/)

[Suzuki M, Yoshioka M, Hashimoto M, et al, Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23400676/)

[Cheng Q, Du Y, Wen L, et al, Vitamin D and Alzheimer's disease: a systematic review and dose-response meta-analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/35708972/)

[Annweiler C, Montero-Odasso M, Schott AM, Berrut G, Fantino B, Beauchet O, Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects (2010)](https://pubmed.ncbi.nlm.nih.gov/20445500/)

[Ceglia L, Harris SS, Vitamin D and its role in skeletal muscle (2013)](https://pubmed.ncbi.nlm.nih.gov/23001444/)

[Yao P, Bennett D, Mafham M, et al, Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis (2019)](https://pubmed.ncbi.nlm.nih.gov/31801642/)

[Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H, Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals (2009)](https://pubmed.ncbi.nlm.nih.gov/18936214/)

[Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ, In vivo imaging of microglial activation with 11C-PK11195 PET in progressive supranuclear palsy (2006)](https://pubmed.ncbi.nlm.nih.gov/16423853/)

[Gezen-Ak D, Dursun E, Ertan T, et al, Association between vitamin D receptor gene polymorphism and Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17543382/)

[Tripkovic L, Lambert H, Hart K, et al, Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis (2012)](https://pubmed.ncbi.nlm.nih.gov/22552031/)

[Sanders KM, Stuart AL, Williamson EJ, et al, Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial (2010)](https://pubmed.ncbi.nlm.nih.gov/20460620/)

[Ross AC, Manson JE, Abrams SA, et al, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know (2011)](https://pubmed.ncbi.nlm.nih.gov/21118827/)

[Annweiler C, Dursun E, Féron F, et al, Vitamin D and cognition in older adults: updated international recommendations (2015)](https://pubmed.ncbi.nlm.nih.gov/26890759/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-vitamin-d-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-vitamin-d-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-57756d364eee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-vitamin-d-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

561

Outgoing

742

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

vitamin-d-therapy-neurodegeneration

Vitamin D Therapy for Neurodegenerative Diseases

Vitamin D Therapy for Neurodegenerative Diseases

Overview

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

VDR Signaling Pathway

Neuroprotective Mechanisms

Pathway Diagram

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Tauopathy Models

Clinical Evidence

Epidemiological Studies

Randomized Controlled Trials

Synthesis of Clinical Evidence

CBS/PSP-Specific Considerations

Falls Prevention — A Primary Indication in PSP

Tau Phosphorylation and 4R-Tauopathy

Neuroinflammation in CBS/PSP

VDR Polymorphisms and Disease Susceptibility

Practical Recommendations for CBS/PSP Patients

Dosing and Formulation Science

Vitamin D3 vs D2

Dosing Strategies

Formulation Considerations

Pharmacokinetics

Drug Interactions and Safety

Safety Profile

Drug Interactions

Contraindications

Combination Therapy Potential

Implementation Workflow for Clinicians

Research Gaps and Future Directions

See Also

References

cites (1)

💬 Discussion

📗 Cite This Artifact

vitamin-d-therapy-neurodegeneration

Vitamin D Therapy for Neurodegenerative Diseases

Vitamin D Therapy for Neurodegenerative Diseases

Overview

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

VDR Signaling Pathway

Neuroprotective Mechanisms

Pathway Diagram

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Tauopathy Models

Clinical Evidence

Epidemiological Studies

Randomized Controlled Trials

Synthesis of Clinical Evidence

CBS/PSP-Specific Considerations

Falls Prevention — A Primary Indication in PSP

Tau Phosphorylation and 4R-Tauopathy

Neuroinflammation in CBS/PSP

VDR Polymorphisms and Disease Susceptibility

Practical Recommendations for CBS/PSP Patients

Dosing and Formulation Science

Vitamin D3 vs D2

Dosing Strategies

Formulation Considerations

Pharmacokinetics

Drug Interactions and Safety

Safety Profile

Drug Interactions

Contraindications

Combination Therapy Potential

Implementation Workflow for Clinicians

Research Gaps and Future Directions

See Also

References

Related Hypotheses

cites (1)

💬 Discussion